Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.525    0.00 (0.00%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £2.38m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Options Award

23 Dec 2025 07:00

RNS Number : 5646M
Physiomics PLC
23 December 2025
 

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZZZZKGKZZ
Date   Source Headline
13th Dec 20217:00 amRNSMerck Contracts
23rd Nov 20213:30 pmRNSResult of AGM
12th Nov 202112:00 pmRNSConference presentation
12th Nov 202112:00 pmRNSConference presentation
27th Oct 20211:00 pmRNSPosting of Annual Report and AGM Notice
22nd Oct 20217:00 amRNSContract awards
30th Sep 20213:00 pmRNSResults Presentation and DoseMeRx Update
30th Sep 20217:00 amRNSFinal Results
16th Sep 20212:45 pmRNSPARNTER study recruits first patient
15th Sep 20217:00 amRNSNotice of Results and Investor Presentation
31st Aug 20217:00 amRNSPhysiomics hires Head of Business Development
19th Jul 20217:00 amRNSPhysiomics expands technical team
29th Jun 20219:16 amRNSDirector Dealing
21st May 20214:40 pmRNSDirector Dealing
21st May 20217:00 amRNSContract awards
14th May 20217:00 amRNSContract award
11th May 20217:00 amRNSContract award
10th May 20217:00 amRNSTrading update
9th Apr 20212:00 pmRNSConference presentation
22nd Mar 20217:00 amRNSDirector/PDMR Shareholding
12th Mar 20217:00 amRNSPresentation and Q&A on Company's Interim Results
4th Mar 20217:00 amRNSInterim Results Presentation
2nd Mar 202110:12 amRNSIssue of Options
1st Mar 20217:00 amRNSInterim Results
15th Feb 20217:00 amRNSValiRx Agreement
18th Dec 20207:00 amRNSHolding(s) in Company
17th Dec 20202:00 pmRNSPartnership with TRHC's DoseMeRx®
17th Dec 20207:00 amRNSMerck Contracts
14th Dec 20207:00 amRNSApproval of NIHR-funded PARTNER study
17th Nov 202012:59 pmRNSResult of AGM
22nd Oct 20208:30 amRNSPosting of Annual Report and AGM Notice
22nd Oct 20207:00 amRNSPosting of Annual Report and AGM Notice
16th Oct 20207:00 amRNSContract awards
6th Oct 20209:00 amRNSPresentation and Q&A on Company’s Final Results
30th Sep 20207:00 amRNSFinal Results and Notice of AGM
25th Sep 20207:00 amRNSFull year results release date and shareholder Q&A
11th Sep 20207:00 amRNSHolding(s) in Company
12th Aug 20207:00 amRNSDirector Dealing
5th Aug 20201:00 pmRNSIssue of Equity
5th Aug 20207:00 amRNSIssue of Equity and Director Dealing
4th Aug 20207:00 amRNSTrading update
31st Jul 20207:00 amRNSPhysiomics awarded contract by Astellas Pharma Inc
22nd Jul 202011:45 amRNSShare Price Movement
17th Jul 20209:00 amRNSPrice Monitoring Extension
6th Jul 202010:00 amRNSDirector dealing
30th Jun 20202:30 pmRNSContract award and update
22nd Jun 20207:00 amRNSConference presentation
10th Jun 20201:00 pmRNSHolding(s) in Company
27th May 20207:00 amRNSFundraise
15th May 20201:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.